CYTOSORBENTS CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
CYTOSORBENTS CORPORATION (CTSO) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 75.60% for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-09.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2024-05-09
- CYTOSORBENTS CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-03-31 was 75.60%, a 7.39% increase year-over-year.
- CYTOSORBENTS CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2023-03-31 was 70.40%, a 18.72% increase year-over-year.
- CYTOSORBENTS CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2022-03-31 was 59.30%.
- CYTOSORBENTS CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2017-03-31 was 71.10%, a 8.49% decline year-over-year.
- CYTOSORBENTS CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2016 was 70.40%, a 5.86% increase from fiscal 2015.
- CYTOSORBENTS CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2015 was 66.50%, a 134.98% increase from fiscal 2014.
- CYTOSORBENTS CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2014 was 28.30%, a 1.07% increase from fiscal 2013.
- CYTOSORBENTS CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2013 was 28.00%, a 0.00% change from fiscal 2012.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 0 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|---|
| 2024-03-31 | 75.60% 10-Q · filed 2024-05-09 | ||||
| 2023-09-30 | 70.90% 10-Q · filed 2023-11-09 | ||||
| 2023-06-30 | 70.60% 10-Q · filed 2023-08-01 | ||||
| 2023-03-31 | 70.40% 10-Q · filed 2023-05-02 | ||||
| 2022-06-30 | 62.90% 10-Q · filed 2022-08-02 | ||||
| 2022-03-31 | 59.30% 10-Q · filed 2022-05-03 | ||||
| 2021-09-30 | 64.70% 10-Q · filed 2022-11-03 | ||||
| 2017-03-31 | 71.10% 10-Q · filed 2017-05-08 | ||||
| 2016-12-31 | 70.40% 10-K · filed 2017-03-03 | ||||
| 2016-09-30 | 68.70% 10-Q · filed 2016-11-07 | ||||
| 2016-06-30 | 72.80% 10-Q · filed 2016-08-09 | ||||
| 2016-03-31 | 77.70% 10-Q · filed 2016-05-09 | ||||
| 2015-12-31 | 66.50% 10-K · filed 2017-03-03 | ||||
| 2015-09-30 | 72.30% 10-Q · filed 2016-11-07 | ||||
| 2015-06-30 | 41.30% 10-Q · filed 2016-08-09 | ||||
| 2015-03-31 | 28.30% 10-Q · filed 2016-05-09 | ||||
| 2014-12-31 | 28.30% 10-K · filed 2017-03-03 | ||||
| 2014-09-30 | 28.30% 10-Q · filed 2014-11-12 | ||||
| 2014-06-30 | 28.30% 10-Q · filed 2014-08-12 | ||||
| 2014-03-31 | 28.30% 10-Q · filed 2014-05-14 | ||||
| 2014-03-11 | 28.30% 10-K · filed 2015-03-31 | ||||
| 2013-12-31 | 28.00% 10-K · filed 2014-03-31 | ||||
| 2013-09-30 | 28.00% 10-Q · filed 2013-11-06 | ||||
| 2013-06-30 | 28.00% 10-Q · filed 2013-08-14 | ||||
| 2013-03-31 | 28.00% 10-Q · filed 2013-05-15 | ||||
| 2012-12-31 | 28.00% 10-K · filed 2013-04-03 | ||||
| 2012-09-30 | 28.00% 10-Q · filed 2012-11-21 | ||||
| 2012-06-30 | 28.00% 10-Q · filed 2012-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |